CUFENCE 100 mg, hard capsule 200 capsules
Active ingredients: Trientine hydrochloride, TRIENTINE
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule200 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- CUFENCE 100 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 1 flacon(s) en verre jaune(brun) avec fermeture de sécurité enfant de 200 gélule(s)
- Marketing authorisation holder
- UNIVAR SOLUTIONS (PAYS-BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Apr 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68588478CIP73028020CIP133400930280201Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TRIENTINEgélule | 100 mg · un gélule | FT |
| DICHLORHYDRATE DE TRIENTINEgélule | 150 mg · un gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.